Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 1.3× sales vs its 2.4× historical median P/S.
Fair value ≈ $12.67 · price $7.02 today
Undervalued · 45% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$ACCD $7.02 bid. *DAC (7) $4.62. EXIT $12.00.
BRIEF:
Accolade: Transcarent announced the successful completion of its merger with Accolade.
note: The transaction, valued at approximately $621 million, has received all necessary regulatory and shareholder approvals and Accolade is now part of a privately held company, and its common stock will no longer be listed on Nasdaq.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
$ACCD $7.02 bid. * DAC (dollar average cost includes 7 transactions to reduce cost to $4.62). Last at $3.60 (6.28.24).
CHANGE EXIT TO $12.00 FROM $8.50.
UPDATE: The merger is tentatively scheduled to close prior to the market open on April 8, 2025, subject to regulatory approval. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on April 7, 2025. If the merger closes as anticipated, the stock will remain halted on the day of closing (April 8th) and will be suspended effective April 9, 2025.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
$ACCD Digging ACCD's personalized healthcare play. Innovative data-driven approach targeting complex healthcare navigation. Watching how they scale and expand their member base. Potential long-term healthcare tech winner. great article: https://beyondspx.com/article/accolade-accd-delivering-personalized-healthcare-solutions-at-scale
1. Accolade Inc. ($ACCD): A healthcare company, Accolade has experienced a significant 97% increase in its stock price over the past 30 days, indicating strong growth potential.
2. Akero Therapeutics Inc. ($AKRO): A biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis (NASH), Akero has seen its stock price rise by 96.2% over the past month.
3. OppFi Inc. ($OPFI): A financial technology company, OppFi has demonstrated a 93.1% increase in its stock price over the past 30 days, suggesting robust growth prospects.
$MPLN $APPS $CRNC $TUYA what I am currently buying/accumulating; they have strong momentum & technical indicators are favorable for either near term bullish move or long term positive move. $ACCD on watch.
$ACCD - Accolade Inc. Common Stock - 10Q - Updated Risk Factors
New risks from the pending Transcarent merger include business disruptions, employee uncertainty, legal challenges, deal restrictions, and significant fallout if it fails. Completion remains uncertain. #Risk
https://d-risk.ai/ACCD/10-Q/2025-01-10
